Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Equity (2017 - 2025)

Historic Return on Equity for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to 0.45%.

  • Akebia Therapeutics' Return on Equity fell 15400.0% to 0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45%, marking a year-over-year decrease of 15400.0%. This contributed to the annual value of 1.74% for FY2024, which is 23600.0% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Return on Equity of 0.45% as of Q3 2025, which was down 15400.0% from 1.36% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Return on Equity registered a high of 8.45% during Q1 2023, and its lowest value of 5.78% during Q1 2022.
  • Its 5-year average for Return on Equity is 0.3%, with a median of 0.21% in 2022.
  • In the last 5 years, Akebia Therapeutics' Return on Equity soared by 142300bps in 2023 and then tumbled by -69600bps in 2024.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Return on Equity stood at 2.69% in 2021, then skyrocketed by 105bps to 0.12% in 2022, then soared by 1088bps to 1.48% in 2023, then dropped by -6bps to 1.39% in 2024, then crashed by -132bps to 0.45% in 2025.
  • Its Return on Equity stands at 0.45% for Q3 2025, versus 1.36% for Q2 2025 and 3.68% for Q1 2025.